A Mountain View company is posting early data from a pancreatic cancer drug program, in which its immunotherapy and chemotherapy combo significantly outperformed chemo on its own.
The clinical-stage company, called ChemoCentryx $CCXI, shared patient survival data from an 18-month Phase Ib trial called CCX872. Testing one of its CCR2 inhibitors alongside chemotherapy regiment Folfirinox, ChemoCentryx saw 29% patient survival at the end of the study.
The company is particularly jazzed about this result when comparing it to a 2011 trial that tested Folfirinox by itself, which saw a 18.2% survival rate.
“The positive findings from our pancreatic cancer trial demonstrate that improved patient survival could result from selectively inhibiting CCR2 with CCX872, thereby blocking the immune-suppressing cells that CCR2 maintains in the tumor environment,” ChemoCentryx CEO Thomas Schall said in a statement. “These data support CCX872 as a very promising, novel immunotherapeutic approach to treating this deadly form of cancer. Building on these highly encouraging results, we look forward to the opportunity to advance CCX872 in combination with other therapies.”
In a disease area like pancreatic cancer, in which survival rates are dismally low, ChemoCentryx’s 29% overall survival rate will get people excited. But when comparing this trial to the 2011 data which tested Folfirinox alone, it’s important to note the differences between the studies. The 2011 trial, which included 342 patients, only enrolled patients with metastatic pancreatic cancer. ChemoCentryx, by comparison, recruited 76% metastatic patients while the rest had locally-advanced pancreatic cancer. The trial included 50 patients total.
ChemoCentryx, whose stock is up 6% in pre-market trading Tuesday, plans to publish and share its data at the ASCO-SITC symposium this weekend.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 31,500+ biopharma pros who read Endpoints News by email every day.Free Subscription